ImmunityBio Surges 11% as ANKTIVA Sales Drive 94% Revenue Growth

NEW YORK, September 30, ImmunityBio, Inc. (IBRX) surged 11.15% after Q4 results showed ANKTIVA-powered revenue up 93.9% year-over-year, catching a 31.3% short float badly positioned against a commercial inflection most had underpriced.

ANKTIVA Delivered the Revenue Ramp, the Cash Position Undercuts It

TTM sales reached $166mn, a 94% jump that repositions ImmunityBio from a clinical-stage story into a commercial one. For a company whose pipeline had been almost entirely pre-revenue, the ANKTIVA ramp is genuine. Free cash flow of -$187mn over the same period complicates that read: ImmunityBio burned more cash than it collected in total sales. The Q4 print confirms ANKTIVA sells; the FCF figure marks the distance still to cover before it sells profitably.

31% Short Float Means Wednesday's Move Was Partly Mechanical

Wednesday's 11% gain was not purely an earnings trade. With 31.3% of the float sold short, covering into a positive print generated mechanical buying pressure that inflates the stock's reaction beyond any genuine shift in fundamental sentiment. The float remains heavily positioned against the company heading into Q1 2026. Another strong ANKTIVA quarter forces further covering; soft guidance produces rapid unwinding in a thin book. Investors buying at $9.44 after the headline pop are entering a position already crowded by momentum.

$187mn in FCF Burn Against $166mn in Revenue Is the Risk the Growth Chart Buries

The revenue figure holds up only until placed against the $187mn FCF deficit, ImmunityBio spends more than it earns in total sales, a gap that closes only through a sharp acceleration in ANKTIVA volumes or additional equity capital. Trailing EPS of -$0.95 per share and a -74.5x forward P/E reflect a market pricing a multi-year path to breakeven. Soon-Shiong's oncology network expansion adds operating leverage, but only if the cash runway survives long enough to reach it.

Full-Year 2026 ANKTIVA Guidance Separates a Durable Ramp from a One-Quarter Comp

The 2026 full-year ANKTIVA net product revenue target is the figure that will determine whether Q4's momentum reflects a structural commercial ramp or a favorable comparison period. Guidance above consensus renews covering pressure on the remaining short float; a range implying deceleration exposes the 94% growth rate as a high-water mark. At $9.44 per share and a -74.5x forward P/E, ANKTIVA volumes must scale materially through 2026, that guidance number is the one that proves the bull thesis wrong if it disappoints.

For a full breakdown of ImmunityBio's fundamentals, cash position, and valuation multiples, generate a Basis Report on IBRX. To stress-test the cash flow trajectory against a range of ANKTIVA growth assumptions, use the DCF calculator.

Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.

Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.